Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 701–800 of 1,008
Focus on myeloproliferative diseases and myelodysplastic syndromes
Etten, R. A. V., & Shannon, K. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.004 · Cited by 93
“In addition, acquired resistance is frequent in advanced CML and can arise from BCR-ABL gene amplification or from point mutations that render the kinase less sensitive to the drug (Gorre et al., 2001).”
BackgroundOncogenic resistance to growth-limiting conditions
Blagosklonny, M. V. (2002) · Nature reviews. Cancer · doi:10.1038/nrc743 · Cited by 92
“asp?DrugCode=1%2D22096&DrugName=GLEEVEC+ORAL&DrugType=1">Glivec ) — an inhibitor of ABL — selects for amplification of BCR–ABL and its mutation”
BackgroundBCR–ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia
Burke, B. A., & Carroll, M. P. (2010) · Leukemia · doi:10.1038/leu.2010.67 · Cited by 92
Jørgensen, H. G., Copland, M., Allan, E. K., Jiang, X., Eaves, A., Eaves, C., & Holyoake, T. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0429 · Cited by 90
“The persistence in most imatinib mesylate–treated patients of a small but molecularly detectable population of leukemic cells is of concern as they represent a potential reservoir from which mutant imatinib mesylate– resistant CML cells may emerge (8).”
BackgroundThe src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases
Shah, N. H., Amacher, J. F., Nocka, L. M., & Kuriyan, J. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1495173 · Cited by 99
“…position in kinases (T315I in c-Abl isoform 1b, residue Thr 338 in c-Src), was the first clinically observed mutation that caused imatinib resistance (Gorre et al. 2001), and it remains the most common resistance mutation to imatinib and related drugs (see PDB code 1EIP for imatinib-bound c-Abl…”
BackgroundChapuy, B., Panse, M., Radunski, U., Koch, R., Wenzel, D., Inagaki, N., Haase, D., Truemper, L., & Wulf, G. G. (2009) · Haematologica · doi:10.3324/haematol.2009.008631 · Cited by 91
Molecular monitoring of chronic myeloid leukemia
Hughes, T. P., & Branford, S. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70023-7 · Cited by 91
Resistance to imatinib (Glivec): update on clinical mechanisms
Weisberg, E., & Griffin, J. D. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00062-1 · Cited by 91
“Investigation of mechanisms of imatinib resistance in patients then led to the discovery of the existence of the T315I mutation in the Abl kinase domain of BCR/ABL, which confers imatinib resistance most likely via sterically blocking imatinib binding to Abl (Gorre et al., 2001).”
BackgroundmiR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein
Li, Y., Wang, H., Tao, K., Xiao, Q., Huang, Z., Zhong, L., Cao, W., Wen, J., & Feng, W. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.02.002 · Cited by 90
Chronic Myeloid Leukemia in 2020
Hehlmann, R. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000468 · Cited by 99
Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647
Gendreau, S. B., Ventura, R., Keast, P., Laird, A. D., Yakes, F. M., Zhang, W., Bentzien, F., Cancilla, B., Lutman, J., Chu, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2590 · Cited by 89
von Bubnoff, N. C. C., Veach, D. R., van der Kuip, H., Aulitzky, W. E., Sänger, J., Seipel, P., Bornmann, W. G., Peschel, C., CLARKSON, B., & Duyster, J. (2005) · Blood · doi:10.1182/blood-2004-06-2445 · Cited by 102
Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors
Hantschel, O. D. (2015) · ACS Chemical Biology · doi:10.1021/cb500886n · Cited by 93
Targeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 106
Chenna, V., Hu, C., Pramanik, D., Aftab, B. T., Karikari, C. A., Campbell, N. R., Hong, S., Zhao, M., Rudek, M. A., Khan, S. R., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0341 · Cited by 92
“The acquisition of secondary resistance to targeted therapies is certainly not unprecedented, with chronic myelogenous leukemia being one of the better known examples where this phenomenon occurs in response to imatinib (31).”
BackgroundTherapy Options in Imatinib Failures
Ramirez, P. A., & DiPersio, J. F. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0170 · Cited by 89
Maley, C. C., Reid, B. J., & Forrest, S. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1375.13.8 · Cited by 89
“Current therapies select for resistance and thus breed their own failure (22-25).”
Pramanik, D., Campbell, N. R., Das, S., Gupta, S., Chenna, V., Bisht, S., Sysa‐Shah, P., Bedja, D., Karikari, C. A., Steenbergen, C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.543 · Cited by 96
“Examples include host and tumor genetic alterations, epigenetic changes, changes in the tumor microenvironment, modification of the drug’s cellular target, or blocking the drug’s entry into the cell [1, 2].”
Klein, S., McCormick, F. P., & Levitzki, A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1651 · Cited by 98
“Occasionally, resistance is due to amplification of the BCR–ABL gen”
BackgroundDrug Resistance to EGFR Inhibitors in Lung Cancer
Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2016) · Chemotherapy · doi:10.1159/000443368 · Cited by 92
Ferrao, P. T., Frost, M. J., Siah, S.-P., & Ashman, L. K. (2003) · Blood · doi:10.1182/blood-2003-01-0083 · Cited by 97
Schoch, C., Haferlach, T., Kern, W., Schnittger, S., Berger, U., Hehlmann, R., Hiddemann, W., & Hochhaus, A. (2003) · Leukemia · doi:10.1038/sj.leu.2402813 · Cited by 95
Wetzler, M., Dodge, R. K., Mrózek, K., Stewart, C. C., Carroll, A. J., Tantravahi, R. V., Vardiman, J. W., Larson, R. A., & Bloomfield, C. D. (2004) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04736.x · Cited by 88
“§§der(17)t(17;18) with similar but not identical break points has also been reported in two cases of AML (Porfiri et al, 1993; Fugazza et al, 1997), one case of NHL (Nordgren et al, 2000) and one case of CML (Sessarego & Ajmar, 1987), a very similar rearrangement, described as der(17;18)(q10;q10), has also been report…”
ResultInfluentialMining the Tumor Phosphoproteome for Cancer Markers
Lim, Y. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2243 · Cited by 102
Kurokawa, M., Zhao, C., Reya, T., & Kornbluth, S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00265-08 · Cited by 85
Tipping, A. J., Mahon, F., Zafirides, G., Lagarde, V., Goldman, J. M., & Melo, J. V. (2002) · Leukemia · doi:10.1038/sj.leu.2402775 · Cited by 91
Chomel, J., & Turhan, A. G. (2011) · Oncotarget · doi:10.18632/oncotarget.333 · Cited by 96
“[14], was shown to confer an absolute resistance to all known ATP-competitive BCRABL inhibitors used in clinical practice [15,16].”
BackgroundCortes, J. E., Hochhaus, A., Hughes, T. P., & Kantarjian, H. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3619 · Cited by 88
“domain as the most common mechanism of resistance.(9) This was soon followed by the development”
BackgroundKuroda, J., Kimura, S. H., Andreeff, M., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Takeuchi, M., Tanaka, R., Murotani, Y., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06899.x · Cited by 87
“…Bcr-Abl-positive (Bcr-Abl+) leukaemias, various Bcr-Abldependent or -independent drug-resistance mechanisms may permit Bcr-Abl+ leukaemic cells to survive and allow disease progression (Mahon et al, 2000; Gorre et al, 2001; Shah et al, 2002; Dai et al, 2004; Donato et al, 2004; Barnes et al, 2005).”
BackgroundKumari, A., Brendel, C. A., Hochhaus, A., Neubauer, A., & Burchert, A. (2011) · Blood · doi:10.1182/blood-2010-08-303495 · Cited by 93
Gleixner, K. V., Ferenc, V., Peter, B., Gruze, A., Meyer, R. A., Hadzijusufovic, E., Cerny‐Reiterer, S., Mayerhofer, M., Pickl, W. F., Sillaber, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2181 · Cited by 87
Khorashad, J. S., Milojković, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A. G., Melo, V. D., Babb, A., de Lavallade, H., Olavarría, E., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096396 · Cited by 87
Grosso, S., Puissant, A., Dufies, M., Colosetti, P., Jacquel, A., Lebrigand, K., Barbry, P., Deckert, M., Cassuto, J., Mari, B. P., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0168 · Cited by 94
Emerging Roles of SIRT1 in Cancer Drug Resistance
Wang, Z., & Chen, W. (2013) · Genes & Cancer · doi:10.1177/1947601912473826 · Cited by 82
“Although the development of BCR-ABL tyrosine kinase inhibitor (TKI) imatinib mesylate significantly advances CML treatment,(83) acquired resistance primarily mediated by genetic mutations of BCR-ABL remains a challenge, in particular, for the advanced phases of the disease.(68,69,84) Mutations of BCR-ABL change the co…”
BackgroundArteaga, C. L., & Baselga, J. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.028 · Cited by 95
STI571: A Paradigm of New Agents for Cancer Therapeutics
Mauro, M. J., O'Dwyer, M. E., Heinrich, M. C., & Druker, B. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.325 · Cited by 127
Kreuzer, K. ‐., le Coutre, P., Landt, O., Na, I., Schwarz, M., Schultheis, K., Hochhaus, A., & Dörken, B. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0644-y · Cited by 87
“suggested that acquired resistance to imatinib is associated with a single amino acid substitution from threonine to isoleucine (Thr315Ile) in the ATP-binding pocket of the c-Abl kinase domain [4].”
BackgroundBCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
Sherbenou, D. W., Hantschel, O., Kaupe, I., Willis, S., Bumm, T., Turaga, L. P., Lange, T., Dao, K.-H., Press, R. D., Druker, B. J., et al. (2010) · Blood · doi:10.1182/blood-2008-10-183665 · Cited by 83
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Pisa, R., & Kapoor, T. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0596-8 · Cited by 86
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors
Hornakova, T., Springuel, L., Devreux, J., Dusa, A., Constantinescu, S. N., Knoops, L., & Renauld, J. (2011) · Haematologica · doi:10.3324/haematol.2010.036350 · Cited by 92
“20 and was also found to be mutated in Imatinib-resistant BCR-ABL positive patients (13, 29, 30) (Figure S2 A, B).”
BackgroundInfluentialBackes, A. C., Zech, B., Felber, B., Klebl, B., & Müller, G. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460440802579975 · Cited by 92
Resistance to Imatinib: Mutations and Beyond
Rosée, P. G. L., & Deininger, M. W. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.06.005 · Cited by 86
Effect of Cellular Quiescence on the Success of Targeted CML Therapy
Komarova, N. L., & Wodarz, D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000990 · Cited by 86
“Imatinib [22,23,25,27,28,34–40].”
BackgroundPharmacogenomics Steps Toward Personalized Medicine
Xie, H., & Frueh, F. W. (2005) · Personalized Medicine · doi:10.2217/17410541.2.4.325 · Cited by 100
“Drug resistance is the result of the mutations (25 amino acid substitutions currently known) within the BCR-ABL kinase domain known to interfere with drug binding and, to a lesser extent, either amplification of the BCR-ABL gene [87] or reduced BCR-ABL dependence [88], thus, a more potent ATP-competitive inhibitor tha…”
BackgroundNoncanonical Amino Acids to Improve the pH Response of pHLIP Insertion at Tumor Acidity
Onyango, J. O., Chung, M. S., Eng, C., Klees, L. M., Langenbacher, R. E., Yao, L., & An, M. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201409770 · Cited by 86
Protein tyrosine kinase inhibitors: new treatment modalities?
Fabbro, D., Parkinson, D., & Matter, A. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00179-0 · Cited by 89
Clinical resistance to imatinib: mechanisms and implications
Hochhaus, A., & Hughes, T. P. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.03.001 · Cited by 90
“The exchange of the amino acids treonine and isoleucine at position 315 of the ABL protein in the type 1a numbering scheme (T315I) was the first mutation detected in resistant patients [16].”
BackgroundInfluentialCardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
Singh, A. P., Umbarkar, P., Tousif, S., & Lal, H. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.05.077 · Cited by 85
Ochi, Y., Yoshida, K., Huang, Y.-J., Kuo, M.-C., Nannya, Y., Sasaki, K., Mitani, K., Hosoya, N., Hiramoto, N., Ishikawa, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23097-w · Cited by 81
“five groups: patients (1) without any TP53 mutations/del(17p)/i(17q), (2) with TP53 mutations alone, (3) with del(17p) alone, (4) with concurrent TP53”
BackgroundGladdy, R. A., Taylor, M. D., Williams, C. J., Grandal, I., Karásková, J., Squire, J. A., Rutka, J. T., Guidos, C. J., & Danska, J. S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00236-2 · Cited by 94
Resistance to c-KIT kinase inhibitors conferred by V654A mutation
Roberts, K. G., Odell, A. F., Byrnes, E. M., Baleato, R. M., Griffith, R., Lyons, A. B., & Ashman, L. K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0641 · Cited by 85
“Examples of this are the T315I substitution in ABL and the homologous T670I substitution in c-KIT (24, 29).”
BackgroundJørgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., & Smith, K. D. (2002) · Blood · doi:10.1182/blood.v99.2.713 · Cited by 85
The Current Status of Drug Discovery Against the Human Kinome
Eglen, R. M., & Reisine, T. (2009) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2008.164 · Cited by 81
Wang, L., Pearson, K., Pillitteri, L., Ferguson, J. E., & Clark, R. E. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03705.x · Cited by 89
“This substitution was shown to confer imatinib resistance in a reconstitution experiment (Gorre et al, 2001).”
BackgroundReddy, T. C., Reddy, D. B., Aparna, A., Arunasree, K. M., Gupta, G., Achari, C., Reddy, G. V., Lakshmipathi, V., Dr.P.S.Subramanyam, A., & Reddanna, P. (2012) · Toxicology in Vitro · doi:10.1016/j.tiv.2011.12.018 · Cited by 84
Rexer, B. N., Engelman, J. A., & Arteaga, C. L. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7324 · Cited by 89
Dorritie, K. A., McCubrey, J. A., & Johnson, D. E. (2013) · Leukemia · doi:10.1038/leu.2013.192 · Cited by 98
Piccaluga, P. P., Paolini, S., & Martinelli, G. (2007) · Cancer · doi:10.1002/cncr.22881 · Cited by 93
Jabbour, E. J., Cortes, J. E., Kantarjian, H. M., Giralt, S., Jones, D. M., Jones, R. B., Giles, F. J., Andersson, B. S., Champlin, R. E., & de Lima, M. (2006) · Blood · doi:10.1182/blood-2006-02-001933 · Cited by 86
Waller, C. F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_1 · Cited by 94
Evolution of resistance to anti-cancer therapy during general dosing schedules
Foo, J., & Michor, F. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.11.022 · Cited by 86
“Analogous mutations lead to acquired resistance to imatinib, a kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) (Gorre et al., 2001).”
STAT signaling in the pathogenesis and treatment of myeloid malignancies
Bar-Natan, M., Nelson, E. A., Xiang, M., & Frank, D. A. (2012) · JAK-STAT · doi:10.4161/jkst.20006 · Cited by 83
“This can occur through further mutations of the kinase, blocking the ability of the drug to bind to the target.(73,74) In addition, activation of other kinases may occur to circumvent the dependence on the inhibited kinase.”
BackgroundZhou, Y., Rideout, W. M., Zi, T., Bressel, A., Reddypalli, S., Rancourt, R. C., Woo, J.-K., Horner, J. W., Chin, L., Chiu, M. I., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1595 · Cited by 88
Jabbour, E. J., Branford, S., Saglio, G. N., Jones, D. M., Cortes, J. E., & Kantarjian, H. M. (2010) · Cancer · doi:10.1002/cncr.25717 · Cited by 82
“1802 Cancer May 1, 2011 dasatinib.46 The T315I mutation forms a hydrogen bond with imatinib through the insertion of a bulky isoleucine, which is thought to disrupt hydrogen bonding and, thus, sterically hinder imatinib binding to BCR-ABL.47,48 In addition, the T315I mutation is associated with an increased affinity f…”
BackgroundHigh-throughput sequencing for noninvasive disease detection in hematologic malignancies
Scherer, F., Kurtz, D. M., Diehn, M., & Alizadeh, A. A. (2017) · Blood · doi:10.1182/blood-2017-03-735639 · Cited by 90
“disease progression, particularly in patients with rising BCR-ABL1 levels.(176-178) Sanger sequencing is presently the primary method for identifying TKI resistance, but remains limited because of poor sensitivity (;10%).”
MethodHershkovitz‐Rokah, O., Modai, S., Pasmanik, M., Toren, A., Shomron, N., Raanani, P., Shpilberg, O., & Granot, G. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.006 · Cited by 83
Resistance to Targeted Therapy in Chronic Myelogenous Leukemia
Hochhaus, A., Erben, P., Ernst, T., & Mueller, M. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2006.12.002 · Cited by 84
Manetti, F., Brullo, C., Magnani, M., Mosci, F., Chelli, B., Crespan, E., Schenone, S., Naldini, A., Bruno, O., Trincavelli, M. L., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701240c · Cited by 81
Conformational disturbance in Abl kinase upon mutation and deregulation
Iacob, R. E., Pene-Dumitrescu, T., Zhang, J., Gray, N. S., Smithgall, T. E., & Engen, J. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811912106 · Cited by 77
“[Note that residues responsible for imatinib drug resistance are most commonly numbered according to the Abl 1a sequence (10)].”
Chernikov, I. V., Gladkikh, D. V., Meschaninova, M. I., Venyaminova, A. G., Аркадьевна, З. М., Vlassov, V. V., & Chernolovskaya, E. L. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.011 · Cited by 84
“The mechanisms of the emergence and development of such resistance include transportation of the drugs out of tumor cells reducing their effective concentration,(14) changes in the efficiency of drug biotransformation,(15,16) accelerated repair of DNA damage in cells,(17) apoptosis blocking,(18) and alterations in the…”
BackgroundLyseng-Williamson, K. A., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161120-00007 · Cited by 94
“[34,35] Drug resistance was associated with reactivation of BCR-ABL signal transduction in studies of Ph+ relapsed patients.[36-38] In one study of 9 patients, this reactivation was associated with a substitution of a single amino acid in a threonine residue of the ABL kinase domain known to form a critical hydrogen b…”
BackgroundLegros, L., Bourcier, C., Jacquel, A., Mahon, F.-X., Cassuto, J. P., Auberger, P., & Pagès, G. (2004) · Blood · doi:10.1182/blood-2003-08-2695 · Cited by 86
O'Hare, T., Eide, C. A., Tyner, J. W., Corbin, A. S., Wong, M. J., Buchanan, S., Holme, K., Jessen, K. A., Tang, C., Lewis, H. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800587105 · Cited by 81
“Relapse is frequently due to Bcr-Abl kinase domain mutations that impair imatinib binding (21, 22, 29).”
BackgroundDrug discovery and the human kinome: Recent trends
Eglen, R. M., & Reisine, T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.007 · Cited by 85
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
Kelly, K. R., Swords, R. T., Mahalingam, D., Padmanabhan, S., & Giles, F. J. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0110-4 · Cited by 81
Protein Kinases as Targets for Cancer Treatment
Giamas, G., Stebbing, J., Vorgias, C. E., & Knippschild, U. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1005 · Cited by 90
“However, mutation of a single amino acid can make a kinase drug resistant, and mutations in ABL that make it resistant to Gleevec are the cause of relapse in patients who have the advanced stage of CML [104].”
BackgroundChemoresistance in Cancer Cells: Exosomes As Potential Regulators of Therapeutic Tumor Heterogeneity
Sharma, A. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0184 · Cited by 81
Cancer drug resistance: A fleet to conquer
Hussain, S., Singh, A., Nazir, S. U., Tulsyan, S., Khan, A., Kumar, R., Bashir, N., Tanwar, P., & Mehrotra, R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28782 · Cited by 86
“For example, in chronic myelogenous leukemia (CML) BCR‐ABL kinase inhibitor imatinib brought complete cytogenic response in the treatment of patients, which led to the development of other inhibitors such as EGFR, BRAF, KIT, etc.(102) Specific molecular targets for other cancers, such as breast, head and neck, colorec…”
BackgroundEbos, J. M. L., Tran, J., Master, Z., Dumont, D., Melo, J. V., Buchdunger, E., & Kerbel, R. S. (2002) · PubMed · Cited by 80
Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers
Tanaka, H., & Watanabe, T. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.019 · Cited by 84
“The adaptive aspect of gene amplification is also a focused issue in tumors, as gene amplification is a measure to antagonize anti-cancer treatments by directly increasing the dosage of target proteins [5] or by activating an alternative cell-proliferation”
BackgroundFerroptosis and Tumor Drug Resistance: Current Status and Major Challenges
Nie, Z., Chen, M., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Wang, F., & Zhang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879317 · Cited by 84
“Similarly, many components in the TME can also affect the sensitivity of tumor cells to drugs (Figure 2).”
BackgroundInfluentialGenomic heterogeneity as a barrier to precision oncology in urothelial cancer
Clinton, T. N., Chen, Z., Wise, H. C., Lenis, A. T., Chavan, S. S., Donoghue, M. T. A., Almassi, N., Chu, C. E., Dason, S., Rao, P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111859 · Cited by 85
“Signatures with a known common source of somatic hypermutation were considered together e.g. signatures 6, 14, 15, 20, 21 and 26 as mismatch-repair deficiency/ MSI-associated.”
Self-citationRole of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
Carrasco‐García, E., Saceda, M., & Martínez-Lacaci, I. (2014) · Cells · doi:10.3390/cells3020199 · Cited by 92
“This phenomenon was initially observed in Imatinib-resistant CML and GIST, where the respective targets, Bcr-Abl and c-Kit acquired a mutation in a “gatekeeper” residue of the ATP-binding pocket [261,262].”
MLL-rearranged leukemias: insights from gene expression profiling
Armstrong, S. A., Golub, T. R., & Korsmeyer, S. J. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)00196-3 · Cited by 79
Tan, D. S. W., Gerlinger, M., Teh, B. T., & Swanton, C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.019 · Cited by 86
Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Reddy, N., O'Brien, S. M., Garcia‐Manero, G., Burger, J. A., & Cortes, J. E. (2008) · Blood · doi:10.1182/blood-2008-04-149948 · Cited by 79
“34 CHR 33 (41%) 11 (55%) 19 (70%) 31 (46%) MCyR 33 (41%) 7 (35%) 6 (23%) 28 (41%) CCyR 24 (30%) 5 (25%) 5 (19%) 19 (28%) Response duration, mo (range) 25 (2-63) 23 (2-69) 20 (1-60) 35 (2-70) .”
Ross, D. M., Branford, S., Moore, S., & Hughes, T. P. (2006) · Leukemia · doi:10.1038/sj.leu.2404139 · Cited by 79
Sherbenou, D. W., Wong, M. J., Humayun, A., McGreevey, L. S., Harrell, P. M., Yang, R., Mauro, M. J., Heinrich, M. C., Press, R. D., Druker, B. J., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404554 · Cited by 79
Cuenco, G. M., & Ren, R. (2001) · Oncogene · doi:10.1038/sj.onc.1205095 · Cited by 83
“Clinical and laboratory studies have demonstrated that BCR-ABL is essential for the induction and maintenance of CML (Daley et al., 1990; Gorre et al., 2001; Heuttner et al., 2000).”
BackgroundCurrent aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia
Balabanov, S., Braig, M., & Brümmendorf, T. H. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.03.003 · Cited by 83
Targeting survival pathways in chronic myeloid leukaemia stem cells
Sinclair, A., Latif, A. L., & Holyoake, T. L. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12183 · Cited by 87
“These mutations are due to different amino acid substitutions resulting in varying degrees of IM resistance, usually due to the inability of the TKI to bind to the kinase domain and thus affecting its activity (Gorre et al., 2001; Branford et al., 2002; Shah et al., 2002).”
BackgroundQuantitative Prediction of Fold Resistance for Inhibitors of EGFR
Balius, T. E., & Rizzo, R. C. (2009) · Biochemistry · doi:10.1021/bi900729a · Cited by 82
“The well-known BCR-Abl kinase resistance mutation at position T315I, referred to as the “gate keeper”, arises from treatment withGleevec (31, 32).”
Wissing, J. B., Godl, K., Brehmer, D., Blencke, S., Weber, M., Habenberger, P., Stein-Gerlach, M., Missio, A., Cotten, M. L., Müller, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400124-mcp200 · Cited by 86
Shah, N. P., & Sawyers, C. L. (2003) · Humana Press eBooks · doi:10.1385/1-59259-308-9:93 · Cited by 78
Self-citationBreast cancer intratumor genetic heterogeneity: causes and implications
Ng, C. K. Y., Pemberton, H. N., & Reis-Filho, J. S. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.85 · Cited by 83
Verstovšek, S., Golemović, M., Kantarjian, H. M., Manshouri, T., Estrov, Z. E., Manley, P. W., Sun, T., Arlinghaus, R. B., Alland, L., Dugan, M. H., et al. (2005) · Cancer · doi:10.1002/cncr.21299 · Cited by 77
Targeting the gatekeeper residue in phosphoinositide 3-kinases
Alaimo, P. J., Knight, Z. A., & Shokat, K. M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.02.021 · Cited by 86
“Indeed, analysis of mutations in BCR-Abl that confer drug resistance has shown that mutation of the gatekeeper to a larger amino acid (T315I) is one of the most common mechanisms of resistance to Gleevec.”
Kretz, O., Weiss, H., Schumacher, M. M., & Groß, G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02117.x · Cited by 80
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
Soverini, S., Benedittis, C. D., Mancini, M., & Martinelli, G. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.035 · Cited by 87
Bagrintseva, K., Schwab, R., Kohl, T. M., Schnittger, S., Eichenlaub, S., Ellwart, J. W., Hiddemann, W., & Spiekermann, K. (2003) · Blood · doi:10.1182/blood-2003-05-1653 · Cited by 85
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.